- Home
- CRDF vs ODC Comparison
CRDF vs ODC Comparison
Compare CRDF & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ODC
- Stock Information
- Founded
- CRDF 1999
- ODC 1941
- Country
- CRDF United States
- ODC United States
- Employees
- CRDF N/A
- ODC N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ODC Miscellaneous manufacturing industries
- Sector
- CRDF Health Care
- ODC Consumer Discretionary
- Exchange
- CRDF Nasdaq
- ODC Nasdaq
- Market Cap
- CRDF 288.7M
- ODC N/A
- IPO Year
- CRDF N/A
- ODC N/A
- Fundamental
- Price
- CRDF $3.06
- ODC $46.54
- Analyst Decision
- CRDF Strong Buy
- ODC
- Analyst Count
- CRDF 4
- ODC 0
- Target Price
- CRDF $12.00
- ODC N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- ODC 53.3K
- Earning Date
- CRDF 05-01-2025
- ODC 03-11-2025
- Dividend Yield
- CRDF N/A
- ODC 1.33%
- EPS Growth
- CRDF N/A
- ODC 18.90
- EPS
- CRDF N/A
- ODC 3.13
- Revenue
- CRDF $683,000.00
- ODC $465,340,000.00
- Revenue This Year
- CRDF N/A
- ODC N/A
- Revenue Next Year
- CRDF N/A
- ODC N/A
- P/E Ratio
- CRDF N/A
- ODC $14.66
- Revenue Growth
- CRDF 39.96
- ODC 8.24
- 52 Week Low
- CRDF $2.01
- ODC $29.48
- 52 Week High
- CRDF $6.38
- ODC $49.72
- Technical
- Relative Strength Index (RSI)
- CRDF 32.85
- ODC 51.61
- Support Level
- CRDF $3.65
- ODC $44.75
- Resistance Level
- CRDF $3.88
- ODC $46.83
- Average True Range (ATR)
- CRDF 0.21
- ODC 1.61
- MACD
- CRDF -0.08
- ODC -0.31
- Stochastic Oscillator
- CRDF 9.30
- ODC 33.72
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").